Healthcare Industry News: XLIF
News Release - July 5, 2006
Hospital Achieves 20% Savings Performing NuVasive's XLIF(R) Lumbar Spinal Fusion ProcedureProvidence Medford Medical Center Documents Savings
SAN DIEGO, Calif., July 5 (HSMN NewsFeed) -- NuVasive, Inc. (Nasdaq: NUVA ), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Providence Medford Medical Center in Medford, OR has recorded a 20% cost savings when using NuVasive's proprietary XLIF® (eXtreme Lateral Interbody Fusion) procedure for lumbar spine fusion surgery compared to a traditional ALIF (anterior) approach.
Providence Medford Medical Center achieved these 20% savings based on a reduction in both "direct" and "indirect" procedure costs. Direct cost savings are primarily achieved through the use of a lesser number of implants. The typical XLIF procedure uses one large implant versus two (or more) implants in the typical ALIF procedure. Indirect hospital costs are those attributable to a hospital's "cost-of-care" such as length of hospital stay, corresponding nursing care and supplies. The XLIF procedure substantially lowered Providence Medford's total cost of care due to substantial reductions in patient tissue disruption, surgery time, and hospital stay in comparison to an ALIF procedure.
The XLIF procedure technique allows spine surgeons to achieve a direct lateral approach to the patient's intervertebral disc space through the psoas muscle as compared to more traditional open procedures which utilize an ALIF (through the abdomen) or PLIF (posterior, through the back muscle) approach. Coupled with NuVasive's NeuroVision® Nerve Avoidance System, the Company's MaXcess® Retraction System allows for maximum surgical access to the spine for addressing the pathology and inserting an interbody implant. This allows for access to the spine through the splitting of muscles, rather than cutting of muscles, thereby minimizing soft tissue dissection and disruption that often occurs during open surgery.
Michael Strasser, Chief Financial Officer of Providence Medford Medical Center, said, "Given the current hospital economic environment, we fully appreciate technologies that can deliver improved patient outcomes with attractive financial benefits. The XLIF procedure is a primary example of this type of technology. On average, we have documented an XLIF average hospitalization time of 1.8 days compared to an average of 4.2 days in prior years when this technology was not available. These metrics are significantly less than what we experienced prior to XLIF and it's clearly positive news for patients, surgeons and hospitals alike."
Dr. Mark Peterson, fellowship trained spine surgeon at Providence Medford Medical Center, said, "In addition to the measurable economic benefits that XLIF provides, the safety profile of the procedure as compared to traditional, more open approaches is greatly improved. This is due to the avoidance of major anatomical structures, drastically mitigating any potential adverse events that have occurred with other types of procedures. I find this advantage especially attractive when operating on elderly or higher-risk patients who are frequently contra-indicated for such an invasive procedure as an ALIF."
Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "Although the cost savings achieved by Providence Medford Medical Center is based on a limited sampling, the data fully supports our view that our MAS Platform and XLIF procedure provide the highest quality benefits to patients in an efficient economic manner. We believe our MAS Platform and XLIF procedure position NuVasive to directly benefit from the increased hospital focus on clinical benefits as well as economics. Our sales force of Area Business Managers and exclusive distributors continue to articulate our technology's benefits to hospitals as we make progress on increasing our share of the spine market."
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $2.9 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings-NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade design retraction system; and specialized implants, like SpheRx® and CoRoent®-that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons, or demonstrate that NuVasive's products and procedures do not provide meaningful cost savings; the risk that NuVasive's XLIF procedure will not produce the intended cost savings as demonstrated by data that becomes available in the future; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.